ML 348

Selective and reversible lysophospholipase 1 (LYPLA1) inhibitor CAS# 899713-86-1

ML 348

Catalog No. BCC5611----Order now to get a substantial discount!

Product Name & Size Price Stock
ML 348: 5mg $115 In Stock
ML 348: 10mg Please Inquire In Stock
ML 348: 20mg Please Inquire Please Inquire
ML 348: 50mg Please Inquire Please Inquire
ML 348: 100mg Please Inquire Please Inquire
ML 348: 200mg Please Inquire Please Inquire
ML 348: 500mg Please Inquire Please Inquire
ML 348: 1000mg Please Inquire Please Inquire
Related Products
  • PR-619

    Catalog No.:BCC3627
    CAS No.:2645-32-1
  • WP1130

    Catalog No.:BCC3686
    CAS No.:856243-80-6

Quality Control of ML 348

Number of papers citing our products

Chemical structure

ML 348

3D structure

Chemical Properties of ML 348

Cas No. 899713-86-1 SDF Download SDF
PubChem ID 3238952 Appearance Powder
Formula C18H17ClF3N3O3 M.Wt 415.79
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : 25 mg/mL (60.13 mM; Need ultrasonic)
Chemical Name N-[2-chloro-5-(trifluoromethyl)phenyl]-2-[4-(furan-2-carbonyl)piperazin-1-yl]acetamide
SMILES C1CN(CCN1CC(=O)NC2=C(C=CC(=C2)C(F)(F)F)Cl)C(=O)C3=CC=CO3
Standard InChIKey OXKNHBBDOIMFFQ-UHFFFAOYSA-N
Standard InChI InChI=1S/C18H17ClF3N3O3/c19-13-4-3-12(18(20,21)22)10-14(13)23-16(26)11-24-5-7-25(8-6-24)17(27)15-2-1-9-28-15/h1-4,9-10H,5-8,11H2,(H,23,26)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of ML 348

DescriptionSelective and reversible lysophospholipase 1 (LYPLA1) inhibitor (IC50 = 210 nM). Exhibits 14-fold selectivity for LYPLA1 over LYPLA2. Also selective over a panel of ~30 other serine hydrolases.

ML 348 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

ML 348 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of ML 348

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.4051 mL 12.0253 mL 24.0506 mL 48.1012 mL 60.1265 mL
5 mM 0.481 mL 2.4051 mL 4.8101 mL 9.6202 mL 12.0253 mL
10 mM 0.2405 mL 1.2025 mL 2.4051 mL 4.8101 mL 6.0127 mL
50 mM 0.0481 mL 0.2405 mL 0.481 mL 0.962 mL 1.2025 mL
100 mM 0.0241 mL 0.1203 mL 0.2405 mL 0.481 mL 0.6013 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on ML 348

ML348 is a selective and reversible lysophospholipase 1 (LYPLA1) inhibitor (IC50 = 210 nM), Exhibits 14-fold selectivity for LYPLA1 over LYPLA2, Also selective over a panel of ~30 other serine hydrolases. target: LYPLA1 [1] IC 50: 210 nM [1]

References:
[1]. Adibekian A et al. Characterization of a Selective, Reversible Inhibitor of Lysophospholipase 1 (LYPLA1). National Center for Biotechnology Information (US); 2010- 2013 Apr 08.

Featured Products
New Products
 

References on ML 348

Fiber-laser-based, high-repetition-rate, picosecond ultraviolet source tunable across 329-348 nm.[Pubmed:28005896]

Opt Lett. 2016 Oct 15;41(20):4799-4802.

We report a compact, fiber-laser-based, high-repetition-rate picosecond source for the ultraviolet (UV), providing multi-tens of milliwatt of average power across 329-348 nm. The source is based on internal sum-frequency-generation (SFG) in a singly resonant optical parametric oscillator (OPO), synchronously pumped at 532 nm by the second harmonic of a picosecond Yb-fiber laser at 80 MHz repetition rate. Using a 30-mm-long single-grating MgO:sPPLT crystal for the OPO and a 5-mm-long BiB3O6 crystal for intracavity SFG, we generate up to 115 mW of average UV power at 339.9 nm, with >50 mW over 73% of the tuning range, for 1.6 W of input pump power. The UV output exhibits a passive rms power stability of approximately 2.9% rms over 1 min and 6.5% rms over 2 h in high beam quality. Angular acceptance bandwidth and cavity detuning effects have also been studied.

Extent of undertreatment and overtreatment with cholesterol-lowering therapy according to European guidelines in 92,348 Danes without ischemic cardiovascular disease and diabetes in 2004-2014.[Pubmed:28038381]

Atherosclerosis. 2017 Feb;257:9-15.

BACKGROUND AND AIMS: We estimated the extent of undertreatment and overtreatment with cholesterol-lowering therapy according to European guidelines in individuals in the Danish general population without ischemic cardiovascular disease and diabetes. METHODS: We examined 92,348 such individuals aged 35-100 years recruited from 2004 through 2014 in the Copenhagen General Population Study. Each individual was assigned their 10-year risk of fatal cardiovascular disease according to the European SCORE chart based on age, sex, smoking, total cholesterol, and systolic blood pressure. European guidelines recommend cholesterol-lowering therapy definitely at >/=10% risk and LDL cholesterol >/=1.8 mmol/L, definitely at 5-9% risk and LDL cholesterol >/=2.5 mmol/L, possibly at 1-4% risk and LDL cholesterol >/=3 mmol/L, but not at <1% risk. RESULTS: 3858 individuals had >/=10% risk, 16,255 had 5-9% risk, 49,131 had 1-4% risk, and 23,104 had <1% 10-year risk of fatal cardiovascular disease. In these groups, 81%, 86%, 93%, and 99% did not receive cholesterol-lowering therapy. Definite undertreatment and overtreatment according to guidelines were found in 19% and 0.2% or in 187,660 and 1570 per million 35-100 year olds without ischemic cardiovascular disease and diabetes. If definite and possible undertreatment and overtreatment were combined, the corresponding numbers were 52% and 3% or 519,416 and 29,194 per million. CONCLUSIONS: In the Danish general population, approximately 190,000 per million 35-100 year olds without ischemic cardiovascular disease and diabetes are not treated to LDL cholesterol goals according to European guidelines. Conversely, approximately 1600 per million received cholesterol-lowering therapy without endorsement in European guidelines.

Pediatric spinal cord astrocytomas: a retrospective study of 348 patients from the SEER database.[Pubmed:28362182]

J Neurosurg Pediatr. 2017 Jun;19(6):711-719.

OBJECTIVE Intramedullary spinal cord tumors comprise 1%-10% of all childhood central nervous system neoplasms, with astrocytomas representing the most common subtype. Due to their rarity and poor prognosis, large population-based studies are needed to assess the epidemiology and survival risk factors associated with these tumors in the hope of improving outcome. The authors undertook this retrospective study to explore factors that may influence survival in pediatric patients with spinal cord astrocytomas. METHODS Utilizing the Surveillance, Epidemiology, and End Results (SEER) database, a prospective cancer registry, the authors retrospectively assessed survival in histologically confirmed, primary spinal cord astrocytomas in patients 21 years of age and younger. Survival was described with Kaplan-Meyer curves, and a multivariate regression analysis was used to assess the association of several variables with survival while controlling for confounding variables. RESULTS This analysis of 348 cases showed that age (hazard ratio [HR] 1.05, 95% CI 1.01-1.09, p = 0.017), nonwhite race (HR 1.74, 95% CI 1.11-2.74, p = 0.014), high-grade tumor status (HR 14.67, 95% CI 6.69-32.14, p < 0.001), distant or invasive extension of the tumor (HR 2.37, 95% CI 1.02-5.49, p = 0.046), and radiation therapy (HR 3.74, 95% CI 2.18-6.41, p < 0.001) were associated with decreased survival. Partial resection (HR 0.37, 95% CI 0.16-0.83, p = 0.017) and gross-total resection (HR 0.39, 95% CI 0.16-0.95, p = 0.039) were associated with improved survival. CONCLUSIONS Younger age appears to be protective, while high-grade tumors have a much worse prognosis. Early diagnosis and access to surgery appears necessary for improving outcomes, while radiation therapy has an unclear role. There is still much to learn about this disease in the hope of curing children with the misfortune of having one of these rare tumors.

Description

ML348 is a selective and reversible lysophospholipase 1 (LYPLA1) inhibitor with an IC50 of 210 nM, and barely inhibits LYPLA2.

Keywords:

ML 348,899713-86-1,Natural Products,Phospholipase, buy ML 348 , ML 348 supplier , purchase ML 348 , ML 348 cost , ML 348 manufacturer , order ML 348 , high purity ML 348

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: